Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575719 | 1.00 | THRB (0.54) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4575725 | 1.00 | THRB (0.54) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4575714 | 1.00 | THRB (0.54) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4575721 | 1.00 | THRB (0.54) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL9602849 | 0.81 | MEN1 (0.35) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10673890 | 0.80 | MEN1 (0.33) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL22346497 | 0.71 | MEN1 (0.45) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| Selfotel SCHEMBL16392882 | 0.70 | MEN1 (1.00) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| Selfotel SCHEMBL20553546 | 0.70 | MEN1 (1.00) | THRBGRIN2DGRIN3BGRIN1GRIN2A | |
| Selfotel SCHEMBL120236 | 0.70 | MEN1 (1.00) | THRBGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | claimed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | claimed |
| US-20220054435-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | STUART L. WEG | 2022-02-24 | — | — | US | disclosed |
| US-20160175266-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160000733-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. | 2016-01-07 | — | — | US | disclosed |
| US-20140171514-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | STUART L. WEG (US) | 2014-06-19 | — | — | US | disclosed |
| US-20080041367-A1 | NMDA Receptor Antagonist Formulation With Reduced Neurotoxicity | JAVELIN PHARMACEUTICALS, INC. | 2008-02-21 | — | — | US | disclosed |
| US-7273889-B2 | Administering ketamine in mixture with carrier; side effect reduction | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20040138298-A1 | Administering ketamine with preservative; side effect reduction; analgesics, anesthetics | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040059003-A1 | Administering ketamine in mixture with carrier; side effect reduction | INNOVATIVE DRUG DELIVERY SYSTEMS, INC. | 2004-03-25 | — | — | US | disclosed |
| US-5614509-A | Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5385903-A | Pharmaceutical agent for treatment of withdrawal symptoms | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-31 | — | — | US | disclosed |
| EP-0488959-A2 | New uses of competitive NMDA receptor antagonists | SANDOZ LTD. (CH) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175266-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | THRB 907/4885GRIN2D 9/4885GRIN3B 7/4885 |
| US-20160000733-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | THRB 907/4885GRIN2D 9/4885GRIN3B 7/4885 |
| US-20040059003-A1 | Administering ketamine in mixture with carrier; side effect reduction | OPRL1, GRIN3A, GRIN2B | THRB 976/4885GRIN2D 19/4885GRIN3B 8/4885 |
| US-20140171514-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | THRB 907/4885GRIN2D 9/4885GRIN3B 7/4885 |
| US-20040138298-A1 | Administering ketamine with preservative; side effect reduction; analgesics, anesthetics | SIGMAR1, KCNAB1, KCNH2 | THRB 562/4885GRIN2D 89/4885GRIN3B 60/4885 |
| US-20220054435-A1 | NMDA RECEPTOR ANTAGONIST FORMULATION WITH REDUCED NEUROTOXICITY | GRIN3A, GRIN2B, GRIN2A | THRB 907/4885GRIN2D 9/4885GRIN3B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.